{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:55:46Z","timestamp":1790286946448,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T00:00:00Z","timestamp":1374624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dermatologic toxicities (<jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content>) to targeted cancer therapy may present as inflammatory dermatoses, keratoses, and as benign and malignant squamous proliferations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Published reports of <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> with cancer therapy with epidermal growth factor receptor (<jats:styled-content style=\"fixed-case\">EGFR<\/jats:styled-content>), tyrosine kinase (<jats:styled-content style=\"fixed-case\">TK<\/jats:styled-content>), <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content>,<jats:styled-content style=\"fixed-case\"> PI<\/jats:styled-content>3K, <jats:styled-content style=\"fixed-case\">AKT<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">BRAF<\/jats:styled-content> inhibitors were reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> associated with targeted cancer therapy demonstrated similar reactions and may be grouped as (i) <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> as cutaneous inflammation, and (ii) <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> as cutaneous epithelial proliferation. <jats:styled-content style=\"fixed-case\">EGFR<\/jats:styled-content> inhibitor, cetuximab, and <jats:styled-content style=\"fixed-case\">MEK<\/jats:styled-content> inhibitors, selumetinib and trametinib, demonstrated papulopustular rash with a suppurative folliculitis in 83%, 93%, and 80% of the patients on therapy, respectively. Common <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> with <jats:styled-content style=\"fixed-case\">EGFR<\/jats:styled-content> inhibitors erlotinib and tyrosine kinase inhibitor sorafenib were hand\u2013foot skin reactions in 30\u201360% of patients on therapy. <jats:styled-content style=\"fixed-case\">PI<\/jats:styled-content>3K inhibitor <jats:styled-content style=\"fixed-case\">BKM<\/jats:styled-content>\u2010120 and <jats:styled-content style=\"fixed-case\">AKT<\/jats:styled-content> inhibitor <jats:styled-content style=\"fixed-case\">MK<\/jats:styled-content>2206 produced maculopapular eruptions seen as dermal hypersensitivity reaction on the skin biopsy. <jats:styled-content style=\"fixed-case\">RAF<\/jats:styled-content> inhibitors vemurafenib and sorafenib were associated with a variety of cutaneous epithelial proliferations (keratosis pilaris, seborrheic keratosis, verruca vulgaris, actinic keratosis, keratoacanthoma, and squamous cell carcinoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Various anticancer agents may target similar cellular compounds and\/or cell signaling pathways thus share similar clinical and histologic features of <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content>. The knowledge of the overlap of <jats:styled-content style=\"fixed-case\">DT<\/jats:styled-content> with different types of targeted cancer therapy will assist in evaluation of cutaneous reactions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.12205","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T19:00:07Z","timestamp":1374692407000},"page":"376-384","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions"],"prefix":"10.1111","volume":"53","author":[{"given":"Jonathan L.","family":"Curry","sequence":"first","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres\u2010Cabala","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin B.","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Tetzlaff","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Y.","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[{"name":"Department of Pathology The University of Texas MD Anderson Cancer Center Houston TX USA"},{"name":"Department of Dermatology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1","volume-title":"More Than 800 Medicines and Vaccines in Testing Offer Hope in the Fight Against Cancer","author":"Tauzin B","year":"2009"},{"key":"e_1_2_6_3_1","first-page":"149","article-title":"Dermatologic toxicities of targeted anticancer therapies","volume":"8","author":"Balagula Y","year":"2010","journal-title":"J Support Oncol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1179\/ACB.66.2.2062526"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e328332d397"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70243-6"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09290.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.06.051"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2001.04226.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0421"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.34.1735"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.04.062"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1590\/S0365-05962011000300010"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm444"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2007.02556.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70385-0"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32833123ed"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9473"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-010-9567-3"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841860903104152"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.070"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.7.886"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08357.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.06.034"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04822.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-1344"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2009.n.003"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.1360"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.5263"},{"key":"e_1_2_6_30_1","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman PB","journal-title":"N Engl J Med"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70270-X"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.10.043"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04791.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2011.01435.x"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.10.018"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-009-0114-0"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdi279"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.665871"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2200"},{"key":"e_1_2_6_40_1","first-page":"114","article-title":"Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the \u201c2011 ASCO Gastrointestinal Cancers Symposium\u201d","volume":"12","author":"Dimou AT","year":"2011","journal-title":"JOP"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70269-3"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2011.04060.x"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000258880"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.6.779"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-5521(99)80088-X"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105358"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.2895"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.7680"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddr029"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09751.x"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.12205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.12205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T12:29:28Z","timestamp":1696336168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.12205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/ijd.12205"],"URL":"https:\/\/doi.org\/10.1111\/ijd.12205","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,24]]},"assertion":[{"value":"2013-07-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}